moderna melanoma - Search News

Moderna, melanoma vaccine and Merck

Moderna stock surges as melanoma vaccine trial shows landmark moment

Moderna and Merck announced study results that reflect a "landmark moment" in treatment for one of the deadliest forms of skin cancer.

· 2d · on MSN

Moderna and Merck say melanoma vaccine succeeded in large trial

· 2d

Merck and Moderna say cancer vaccine shows promise in preventing recurrence of melanoma

· 1d

Moderna, Merck breakthrough could usher in wave of cancer vaccines

Merck and Moderna’s success with a personalized cancer vaccine designed to keep melanoma at bay opens a new avenue of treatment that doctors hope will work against many types of tumors.

· 1d

Moderna’s personalized mRNA shot could reshape the fight against skin cancer — but it may also be overhyped

· 1d

Moderna breakthrough brings back memories of pandemic mania

· 1d

Moderna shares get a shot in the arm after cancer vaccine results

Elsewhere, the Evergrande saga came to a dramatic conclusion in a Shenzhen court.

· 1d

⚡Flash Heard: Why Healthcare Is Partying Like It’s Late 2020

· 1d

Moderna, Merck develop vaccine that could help fight against melanoma

COVID-era juggernaut Moderna spikes 177% after successful late-stage trial for melanoma drug

Moderna has been looking for its next blockbuster drug after a wildly successful COVID era.

Doctors explain how Moderna's melanoma mRNA vaccine could fight deadliest form of skin cancer

CBS News medical correspondent Dr. Céline Gounder, who has had melanoma herself, said Moderna's experimental trial is "a big win for mRNA vaccines against cancer."

Medical News Today

Novel mRNA vaccine plus immunotherapy reduces melanoma relapse in phase 3 trial

Moderna and Merck's neoantigen treatment, combining a personalized mRNA cancer vaccine with the immunotherapy drug pembrolizumab significantly reduced the risk of melanoma recurrence in a phase 3 trial.

24/7 Wall St.

Moderna Rallies 8%, BioNTech Climbs 4% as the mRNA Trade Whipsaws for a Third Session

Moderna has now swung violently in both directions for three straight sessions on the same unchanged clinical news, and the options chain hints at why this whipsaw is far from over.

Moderna's cancer vaccine hits key goal in melanoma trial with NYU Langone link

Moderna shares jumped this week after the company announced encouraging results from a late-stage melanoma trial.

Moderna oncology platform draws Street value after melanoma trial win

Moderna Inc (NASDAQ:MRNA, XETRA:0QF)'s melanoma trial success is prompting Wall Street to assign new platform value to the company's oncology pipeline, Jefferies said, as investors look beyond its COVID-dependent revenue base.

BioSpace

Merck’s Moderna-partnered vaccine success clears view of post-Keytruda future

Investors had been pessimistic about the probability of success for the personalized cancer vaccine intismeran autogene, so the Phase 3 win was a welcome surprise.